We have investigated the effect of enterostatin on insulin release by the perfused rat pancreas: (1) under conditions of prolonged fasting and (2) under beta cell stimulation by digestive insulinotropic piptides. RESULTS: In pancreases from 24-h starved rats, the insulin response to glucose was reduced ( $ 75%) as compared to that observed in fed rats. This minimal response was abolished by 100 nM enterostatin. In fed rats, 100 nM enterostatin blocked the insulin output evoked by gastric inhibitory peptide (GIP) ( $ 75%) and by glucagon-like peptide-1 (GLP-1) ( $ 80%). Since both peptides exert their insulinotropic activity by activating the adenylate cyclaseacyclic AMP system, the interference of this pathway by enterostatin may be considered. Enterostatin (100 nM) did not modify the insulin responses to 26 ± 33 fragment of cholecystokinin (CCK-8) and carbachol, substances which activate phosphoinositol turnover within the beta cell. The inhibitory effect of 100 nM enterostatin on glucose-induced insulin release was also observed at 50 nM and 10 nM enterostatin. Finally, des-Arg-enterostatin (100 nM) did not modify glucose-induced insulin output. CONCLUSION: Enterostatin inhibits the insulin response to glucose Ð both under fed and fasted conditions, and to the main digestive insulinotropic peptides Ð GIP and GLP-I. The entire enterostatic molecule seems to be necessary for it to exert its beta cell blocking effect. While the physiological role of enterostatin has not as yet been established, our observations allow speculation as to whether this peptide is implicated in the entero-insular axis as an antiincretin agent.
Introduction
Enterostatin is a pentapeptide generated in the small intestine as a result of tryptic digestion of pancreatic procolipase. 1 It has a highly conserved structure across several mammalian species, thus suggesting a possible physiological role for this peptide. 2 Enterostatin has been shown to inhibit food intake in fasted rats, producing early satiety; 3 this anorectic property is speci®c towards fat intake. 4, 5 These ®ndings, together with the observation of reduced levels of procolipase in the pancreas of hyperphagic, obese Zucker rats, 6 are consistent with the concept of enterostatin as a key modulator of food intake. 7 Besides its anorectic effect, it has been found that acute i.v. injection of enterostatin in overnight fasted rats inhibits the insulin response to an i.v. glucose bolus, 8 and that intraduodenal instillation of enterostatin blocks the elevation of plasma insulin levels induced by enteral administration of Intralipid. 9 Indeed, it is conceivable that a reduction of energy intake is associated with reduced insulin need. Furthermore, in vitro studies have shown that enterostatin inhibits insulin release evoked by glucose, 10, 11 arginine, or tolbutamide. 11 Preinfusion of the rat pancreas with enterostatin does not modify its subsequent insulin response to glucose, this excluding a toxic effect of this pentapeptide on the beta cell. 11 As for the effect of enterostatin on unstimulated insulin secretion, Mei and Erlanson-Albertsson 8 reported that i.v. injection of this peptide (170 nmolaKg) in rats did not modify basal plasma insulin levels, while at a higher dose (340 nmolaKg) it produced an elevation of circulating insulin. Chronic intravenous 8 or introcerebroventricular 12 administration of enterostatin has been shown to decrease basal insulin levels.
To further characterize the insulinostatic effect of enterostatin, we have investigated its in¯uence on insulin release: (1) under conditions of beta cell resting activity, i.e., prolonged fasting and (2) under beta cell stimulation by secretagogues that interact at two different levels of the beta cell stimulus-secretion coupling, namely by activating the adenylate cyclasea cyclic AMP system (gastric inhibitory peptide (GIP) and glucagon-like peptide 1 (GLP-1)), and by increasing the phospholipid turnover within the beta cell (the 26 ± 33 fragment of cholecystokinin, CCK-8 and carbachol). In addition, we have examined the effect of des-Arg-enterostatin, the main metabolite of enterostatin hydrolysis by intestinal membranes, on the insulin response to glucose. The study was performed in the isolated rat pancreas perfused in situ.
Methods
Male Wistar rats (200 ± 225 g body weight) fed ad libitum were used as donors. In a series of experiments, rats were starved for 24 h immediately prior to the perfusions. Animals were maintained in accordance with the guidelines established by the European Union (86a609). After anaesthesia of the rat with pentobarbital sodium (50 mgakg, i.p.), the pancreas was dissected and perfused in situ. 13 Ef¯uent samples were collected from the portal vein, without recycling, at one-minute intervals (¯ow rate, 2 mlamin), and frozen at 7 20 C until the time of assay. The perfusion medium consisted of a Krebs ± Henseleit buffer: 115 mM NaCI, 4.7 mM KCI, 2.6 mM CaCI 2 , 1.19 mM H 2 KPO 4 ,1.19 mM MgSO 4 .7H 2 O and 24.9 mM NaHCO 3 (gas phase 95.5, 0 2 :CO 2 ; pH 7.4), supplemented with 4% (wtavol) dextran T-70 (Pharmacia LKB Biotechnology, Uppsala, Sweden), 0.5% (wtavol) Cohn Fraction V bovine albumin (Sigma Chemical Co., St. Louis, MO, USA) and 5.5 mM glucose (Sigma). Synthetic rat enterostatin and synthetic rat des-Arg-enterostatin (Peninsula Laboratories, Inc., Belmont, CA, USA) were each dissolved in 0.9% NaCI containing 0.1% bovine albumin (Cohn Fraction V). both solutions (1.78 mM) were prepared daily, immediately before experiments. When added to the perfusage, the ®nal concentration was 100 nM. After a 35 min equilibration period, baseline samples were collected for 5 min. Rat enterostatin or des-Argenterostatin, with or without addition of beta cell secretagogues ± 9 mM glucose, 1 nM GIP (Peninsula Labs.), 1 nM GLP-I (Peninsula Labs.), 1 nM CCK-8 (Peninsula Labs.), and 1 mM carbachol (Sigma), were infused through a sidearm cannula at the times shown on the corresponding ®gures. In a further series of experiments, the effects of three concentrations of enterostatin (100 nM, 50 nM and 10 nM) on glucoseinduced insulin release were compared. Insulin was measured by radioimmunoassay.
14 Anti-pig insulin serum (18510, Sigma) and rat insulin standards (Novo, Nordisk, Denmark) were employed. Interand intra-assay coef®cients of variation were less than 6% and 4% respectively. All samples for each series of experiments were analyzed within the same assay. Results are presented as the mean AE s.e.m. Hormone response was calculated as the integrated area of the curve above the mean preinfusion level (average of all the baseline levels for each perfusion) using the trapezoidal method. Differences between values were tested for signi®cance by analysis of variance and by the Student's t-test for unpaired samples.
Results
In a ®rst series of experiments (Figure 1) , we studied the effect of enterostatin on glucose-induced insulin release in 24 h starved rats. As expected, the insulin response to glucose observed in fed rats (incremental area: 137AE 32 nga20 min, n 5) was markedly reduced by starvation (incremental area: 36 AE 10 nga 20 min, n 4; P`0.05). The small insulin response to glucose observed in starved rats were blocked by 100 nM enterostatin (incremental area: 36AE 10 nga 20 min, n 4 vs, 9.8 AE 2.6 nga20 min, n 4 in enterostatin perfusions; P`0.05).
Subsequent experiments were performed in fed rats. The effects of 100 nM enterostatin on insulin secretion at constant 5.5 mM glucose infusion and on GIPinduced insulin release are shown in Figure 2 . Enterostatin did not signi®cantly modify insulin secretion at 5.5 mM glucose (F 5,20 0.28) but clearly inhibited the insulin response elicited by 1 nM GIP (incremental area: 8 AE 9 nga20 min, n 5 vs, 31AE 9 nga20 min, n 6 in control experiments; P`0.025). Both phases of GIP-induced insulin secretion were suppressed during enterostatin infusion.
As depicted in Figure 3 , 100 nM enterostatin virtually abolished the insulin responses to 1 nM GLP-I (incremental area: 36AE 22 nga20min, n 5 vs 213 AE 44 nga20 min, n 5 in control experiments; P`0.05). Figure 4 shows the insulin responses to 1 nM CCK-8 in the presence and in the absence of 100 nM enterostatin. Under both conditions, the insulin response curves overlapped. Similarly, enterostatin did not signi®cantly (P 0.945) modify the insulin release elicited by 1 mM carbachol ( Figure 5 ). Figure 1 Insulin responses to increasing perfusate glucose concentration from 5.5 mM ± 9 mM, in the perfused rat pancreas. Thick line corresponds to glucose infusion in fed rats (n 5). Thin line corresponds to glucose infusion in 24-h starved rats (n 4). Broken line corresponds to 100 nM enterostatin plus glucose infusion in 24 h starved rats (n 4). Means AE s.e.m.
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The effect of enterostatin and its metabolite des-Arg-enterostatin on glucose-induced insulin release are compared in Figure 6 . As expected, 100 nM enterostatin markedly blocked the insulin response to an increase in glucose concentration from 5.5 mM to 9 mM glucose (incremental area: 22 AE 16 nga20 min, n 7 vs, 112 AE 31 nga20 min, n 6 in control experiments; P`0.025). However, pancreases perfused with 100 nM des-Arg-enterostatin showed an insulin response to said glucose stimulus comparable to that found in control experiments (incremental area: 97.4 AE 25 nga20 min, n 6 vs, 90AE 20 nga20 min, n 6 in control experiments; P 0.83). Finally Figure 7 shows the insulin responses to an increase in perfusate glucose concentration from 5.5 mM to 9 mM, in the presence of 100 nM, 50 nM and 10 nM enterostatin. The insulinostatic effect of 100 nM enterostatin (Figure 1 and Figure 7) was also observed at lower concentrations of this peptide: at 50 nM enterostatin (incremental area: 25 AE 8 nga 20 min vs, 86AE 8 nga20 min in control experiments; Effect to 100 nM rat enterostatin on the insulin response to 1mM carbachol at 5.5 mM glucose. Solid line corresponds to control experiments: from 0 ± 5 min, saline infusion; from 5 ± 25 min, carbachol infusion (n 6). Broken line corresponds to enterostatin experiments: from 0 ± 5 min, enterostatin infusion; from 5 ± 25 min, carbachol plus enterostatin infusion (n 6). Means AE s.e.m. Figure 2 Effect of 100 nM rat enterostatin on the insulin response to 1 nM GIP at 5.5 mM glucose in the perfused rat pancreas. Solid line corresponds to control experiments: from 0 ± 5 min, saline infusion; from 5 ± 25 min, GIP infusion (n 6). Broken line corresponds to enterostatin experiments: from 0 ± Enterostatin and insulin secretion J Rodrõ Âguez-Gallardo et al P`0.01) and at 10 nM enterostatin (incremental area: 50AE 7 nga20 min; P`0.025 vs, control experiments).
Discussion
The foregoing results con®rm the inhibitory effect of enterostatin on glucose-induced insulin secretion in perfused pancreases from fed rats, 11 and demonstrate a similar inhibitory effect for this peptide in pancreases from rats subjected to 24 h starvation. After a period of 24 h of food deprivation, the insulin response to an elevation of the glucose concentration in the perfusate which may be regarded as`physiological' (from 5.5 ± 9 mM) was reduced by 75% as compared to that observed in pancreases from fed rats. This ®nding is in agreement with previous in vitro studies recently reviewed by Stein et al. 15 Addition of 100 nM enterostatin to the perfusate virtually abolished this minimal insulin response. Thus, in a state of beta-cell resting activity, enterostatin maintains its insulinostatic effect.
In pancreases from fed rats, enterostatin markedly blocked the insulin secretion evoked by both GIP and GLP-I. These two peptides, released after ingestion of carbohydrates and of fat stimulate insulin secretion by binding to speci®c receptors coupled to adenylate cyclase and promoting the formation of cyclic AMP. 18, 19 Thus, enterostatin may block their insulinotropic effect by interfering with the adenylate cyclaseacyclic AMP system. Such a mechanism might also account for enterostatin blockade of glucose-induced insulin secretion, a process associated with an increase in beta-cell cyclic AMP concentrations. 20 Our observation of the inhibitory effect of enterostatin on GIP-induced insulin release is in accordance with studies in humans showing that fat ingestion provokes an increase in plasma GIP without affecting plasma insulin levels. 21, 22 Similarly, the elevation of GLP-I after fat ingestion is not accompanied by an increase in circulating insulin. 21 Thus, it can be thought that the release of enterostatin induced by fat ingestion might contribute to the absence of insulin response to these insulinotropic hormones.
Enterostatin, however, did not modify the insulin secretion induced by CCK-8. This CCK fragment acts on the beta cell through stimulation of phospholipase C, subsequent activation of protein kinase C and Figure 6 (A) Effect to 100 nM rat enterostatin on the insulin response to increasing glucose concentration from 5.5 ± 9 mM in the perfused rat pancreas. Solid line corresponds to control experiments: from 0 ± 5 min, saline infusion; from 5 ± 25 min, 9 mM glucose infusion (n 6). Broken line corresponds to enterostatin experiments: from 0 ± 5 min, enterostatin infusion; from 5 ± 25 min, 9 mM glucose plus enterostatin infusion (n 7). Means AE s.e.m. (B) Effect to 100 nM des-Arg-enterostatin on the insulin response to increasing glucose concentration from 5.5 ± 9 mM in the perfused rat pancreas. Solid line corresponds to control experiments: from 0 ± 5 min, saline infusion; from 5 ± 25 min, 9 mM glucose infusion (n 6). Broken line corresponds to desArg-enterostatin experiments: from 0 ± 5 min, des-Arg-enterostatin infusion; from 5 ± 25 min, 9 mM glucose plus des-Arg-enterostation infusion (n 6). Means AE s.e.m. Figure 7 Insulin responses (integrated area) to increasing glucose concentration from 5.5 ± 9 mM in the perfused rat pancreas. Solid line corresponds to control experiments, performed in the absence of enterostatin (n 5). Shaded bars correspond to enterostatin experiments; 10 nM (n 4); 50 nM (n 4); 100 nM (n 4). Means AE s.e.m.
Enterostatin and insulin secretion J Rodrõ Âguez-Gallardo et al increasing cytosolic Ca 2 concentrations by mobilization of its intracellular stores. 23, 24 Therefore, it seems that this pathway, which plays an important role in beta cell secretion, is enterostatin independent. In agreement with this ®nding, enterostatin also failed to modify the insulinotropic effect of carbachol, a cholinergic agonist also known to activate phosphoinositol turnover within the beta cell. 24 The differential effects of enterostatin on insulin release elicited by secretagogues acting on the beta cell via different mechanisms would indicate that this peptide affects speci®c levels of the beta-cell stimulus-secretion coupling mechanism, not acting as a general insulinostatic agent but by interfering with a distal, crucial step in this secretory process.
Information about the concentration of enterostatin in circulating blood is scarce. In normal subjects, basal plasma enterostatin concentrations have been found to be 20 ± 40 nM (23, 25) . Similar values (50 AE 4 nM) have been reported for the serum of normal rates. 26 Bowyer et al, 25 have shown that after consumption of a standard meal, circulating enterostatin rises to up to 100 nM. According to these data, the enterostatin concentrations employed in our perfusions (100 nM, 50nM and 10nM) would fall within the physiological range, thus supporting the concept of this peptide as an endogenous inhibitory agent of beta cell secretion. Interestingly, it has recently been reported that in obese subjects, hyperinsulinaemia is associated with a reduced circulating level of enterostatic. 27 It has been demonstrated that enterostatin is hydrolyzed by intestinal brain membranes, involving the removal of C-terminal arginine by carboxypeptidase C and leading to the production of des-Arg-enterostatin as the main metabolite. 28 This enterostatin fragment, at pharmacological concentrations ± in the micromolar range, has been found to exert a blocking effect on glucose-induced insulin release, comparable to that of enterostatin, in rat islets. 29 In our perfused pancreas system, des-Arg-enterostatin did not modify glucose-induced insulin release when infused at 100 nM, a concentration at which enterostatin consistently blocks insulin secretion. Therefore, the entire enterostatin molecule seems to be necessary for exerting its insulinostatic effect. In fact, Mei et al, 9 have shown that, in contrast to enterostatin, intraduodenal infusion of des-Arg-enterostatin did not suppress plasma insulin concentrations in rats.
Conclusion
In the rat pancreas, enterostatin, as putatively physiological concentrations, effectively inhibits the insulin response to glucose and to the main digestive insulinotropic peptides ± GIP and GLP-I. These observations suggest a role for enterostatin in the entero-insular axis as an anti-incretin agent.
